All In MedTech

Device Trial Radar · NCT07902739

Pulsed Field Ablation of Atrial Fibrillation: CENTAURI Versus FARAPULSE

Prospective Randomized Clinical Comparison of Catheter Ablation of Atrial Fibrillation Using the CENTAURI PEF System and the FARAPULSE System

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 325 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

325

Actual

Start

May 17, 2024

Primary completion

Oct 5, 2026

Study completion Oct 5, 2026

Sponsor

Lead sponsor
St. Anne's University Hospital Brno, Czech RepublicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 29, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to compare the efficacy of two commercially available pulsed field ablation (PFA) systems for catheter ablation of atrial fibrillation. Patients are randomized 1:1 to point-by-point PFA using the CENTAURI PEF system with 3D electroanatomical mapping, or to single-shot PFA using the FARAPULSE pentaspline catheter guided by fluoroscopy and intracardiac echocardiography. The primary endpoint is freedom from documented atrial arrhythmia recurrence between 3 and 12 months after ablation.

Conditions

  • Atrial Fibrillation (AF)
  • Paroxysmal AF
  • Persistent AF

Interventions

  • CENTAURI PEF systemDevice

    Point-by-point pulsed field ablation using the CENTAURI generator connected to a contact-force sensing focal ablation catheter (TactiCath SE, Abbott), guided by the EnSite Precision 3D electroanatomical mapping system (Abbott). Pulmonary vein isolation is performed in all patients; additional ablation of low-voltage areas is at the operator's discretion. Procedure performed under general anesthesia.

  • FARAPULSE systemDevice

    Single-shot pulsed field ablation using the FARAPULSE system (Boston Scientific) with a multielectrode pentaspline ablation catheter, guided by fluoroscopy and intracardiac echocardiography without a 3D mapping system. Pulmonary vein isolation is performed in all patients; additional ablation of low-voltage or fractionated areas is at the operator's discretion. Procedure performed under general anesthesia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Freedom from atrial arrhythmia recurrenceTime frame: 3 to 12 months after ablation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. Anne's University Hospital Brno

    Brno, Czechia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.